Annual Operating Profit
-$33.32 M
-$6.75 M-25.42%
30 September 2022
Summary:
NeuBase Therapeutics annual operaing income is currently -$33.32 million, with the most recent change of -$6.75 million (-25.42%) on 30 September 2022. During the last 3 years, it has fallen by -$6.75 million (-25.42%).NBSE Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Operating Profit
-$1.59 M
+$2.10 M+56.87%
30 September 2023
Summary:
NeuBase Therapeutics quarterly operating income is currently -$1.59 million, with the most recent change of +$2.10 million (+56.87%) on 30 September 2023.NBSE Quarterly Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Operating Profit
-$13.38 M
+$6.13 M+31.42%
30 September 2023
Summary:
NeuBase Therapeutics TTM operating income is currently -$13.38 million, with the most recent change of +$6.13 million (+31.42%) on 30 September 2023.NBSE TTM Operating Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NBSE Operating Profit Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | -25.4% | +77.8% | +49.6% |
| 5 y5 years | -30.6% | +92.9% | +47.5% |
NBSE Operating Profit High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | ||||||
| 5 y | 5 years | ||||||
| alltime | all time | -362.2% | -112.5% | -159.1% |
NeuBase Therapeutics Operating Profit History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2023 | - | -$1.59 M(-56.9%) | -$13.38 M(-31.4%) |
| June 2023 | - | -$3.69 M(-11.3%) | -$19.52 M(-19.3%) |
| Mar 2023 | - | -$4.16 M(+5.3%) | -$24.19 M(-19.3%) |
| Dec 2022 | - | -$3.95 M(-48.9%) | -$29.96 M(-10.1%) |
| Sept 2022 | -$33.32 M(+25.4%) | -$7.72 M(-7.6%) | -$33.32 M(+1.7%) |
| June 2022 | - | -$8.36 M(-15.8%) | -$32.76 M(-1.4%) |
| Mar 2022 | - | -$9.93 M(+35.9%) | -$33.24 M(+13.8%) |
| Dec 2021 | - | -$7.30 M(+1.9%) | -$29.21 M(+10.0%) |
| Sept 2021 | -$26.57 M(+55.6%) | -$7.17 M(-18.9%) | -$26.57 M(+8.4%) |
| June 2021 | - | -$8.84 M(+49.9%) | -$24.50 M(+25.7%) |
| Mar 2021 | - | -$5.90 M(+26.5%) | -$19.49 M(+8.6%) |
| Dec 2020 | - | -$4.66 M(-8.7%) | -$17.95 M(+5.1%) |
| Sept 2020 | -$17.07 M(-33.1%) | -$5.11 M(+33.6%) | -$17.07 M(-50.2%) |
| June 2020 | - | -$3.82 M(-12.2%) | -$34.28 M(+8.5%) |
| Mar 2020 | - | -$4.36 M(+15.1%) | -$31.59 M(+11.3%) |
| Dec 2019 | - | -$3.78 M(-83.0%) | -$28.39 M(+11.3%) |
| Sept 2019 | -$25.51 M(+181.0%) | -$22.31 M(+1862.7%) | -$25.51 M(+499.7%) |
| June 2019 | - | -$1.14 M(-1.4%) | -$4.25 M(-0.7%) |
| Mar 2019 | - | -$1.15 M(+27.2%) | -$4.28 M(-6.3%) |
| Dec 2018 | - | -$906.40 K(-14.3%) | -$4.57 M(-41.7%) |
| Sept 2018 | -$9.08 M(-61.9%) | -$1.06 M(-9.3%) | -$7.85 M(-34.9%) |
| June 2018 | - | -$1.17 M(-19.2%) | -$12.05 M(-18.6%) |
| Mar 2018 | - | -$1.44 M(-65.5%) | -$14.81 M(-29.7%) |
| Dec 2017 | - | -$4.18 M(-20.5%) | -$21.06 M(-11.7%) |
| Sept 2017 | -$23.85 M(-5.8%) | -$5.26 M(+33.9%) | -$23.85 M(-6.1%) |
| June 2017 | - | -$3.93 M(-48.9%) | -$25.40 M(-12.6%) |
| Mar 2017 | - | -$7.69 M(+10.2%) | -$29.07 M(+1.3%) |
| Dec 2016 | - | -$6.98 M(+2.4%) | -$28.69 M(+13.4%) |
| Sept 2016 | -$25.31 M(+44.9%) | -$6.81 M(-10.4%) | -$25.31 M(+15.3%) |
| June 2016 | - | -$7.60 M(+4.0%) | -$21.96 M(+24.1%) |
| Mar 2016 | - | -$7.31 M(+103.4%) | -$17.69 M(+2.9%) |
| Dec 2015 | - | -$3.59 M(+3.9%) | -$17.19 M(-1.9%) |
| Sept 2015 | -$17.47 M(+91.5%) | -$3.46 M(+3.7%) | -$17.52 M(+2.2%) |
| June 2015 | - | -$3.33 M(-51.0%) | -$17.14 M(+8.1%) |
| Mar 2015 | - | -$6.81 M(+73.4%) | -$15.86 M(+43.9%) |
| Dec 2014 | - | -$3.92 M(+27.5%) | -$11.03 M(+20.9%) |
| Sept 2014 | -$9.12 M(+97.4%) | -$3.08 M(+49.8%) | -$9.12 M(+16.3%) |
| June 2014 | - | -$2.06 M(+4.4%) | -$7.85 M(+10.1%) |
| Mar 2014 | - | -$1.97 M(-2.6%) | -$7.13 M(+22.3%) |
| Dec 2013 | - | -$2.02 M(+12.2%) | -$5.83 M(+26.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2013 | -$4.62 M(+40.6%) | -$1.80 M(+35.0%) | -$4.62 M(+13.7%) |
| June 2013 | - | -$1.34 M(+99.9%) | -$4.07 M(+20.8%) |
| Mar 2013 | - | -$668.10 K(-18.0%) | -$3.36 M(-6.6%) |
| Dec 2012 | - | -$814.80 K(-34.7%) | -$3.60 M(+9.7%) |
| Sept 2012 | -$3.29 M(+164.3%) | -$1.25 M(+96.5%) | -$3.29 M(+36.1%) |
| June 2012 | - | -$634.70 K(-30.1%) | -$2.42 M(+16.0%) |
| Mar 2012 | - | -$907.50 K(+82.5%) | -$2.08 M(+49.7%) |
| Dec 2011 | - | -$497.20 K(+32.4%) | -$1.39 M(+11.8%) |
| Sept 2011 | -$1.24 M(+22.4%) | -$375.60 K(+24.6%) | -$1.24 M(+3.9%) |
| June 2011 | - | -$301.50 K(+39.6%) | -$1.20 M(-4.3%) |
| Mar 2011 | - | -$215.90 K(-38.4%) | -$1.25 M(+3.5%) |
| Dec 2010 | - | -$350.30 K(+6.6%) | -$1.21 M(+18.9%) |
| Sept 2010 | -$1.02 M(+8.9%) | -$328.60 K(-7.3%) | -$1.02 M(+13.4%) |
| June 2010 | - | -$354.60 K(+104.0%) | -$895.70 K(+18.2%) |
| Mar 2010 | - | -$173.80 K(+9.7%) | -$757.70 K(-26.0%) |
| Dec 2009 | - | -$158.50 K(-24.1%) | -$1.02 M(+9.9%) |
| Sept 2009 | -$932.90 K(+39.9%) | -$208.80 K(-3.6%) | -$932.20 K(-10.0%) |
| June 2009 | - | -$216.60 K(-50.8%) | -$1.04 M(+24.3%) |
| Mar 2009 | - | -$440.40 K(+563.3%) | -$833.40 K(+70.4%) |
| Dec 2008 | - | -$66.40 K(-78.8%) | -$489.00 K(-26.5%) |
| Sept 2008 | -$666.60 K(<-9900.0%) | -$312.60 K(+2132.9%) | -$665.60 K(+88.6%) |
| June 2008 | - | -$14.00 K(-85.4%) | -$353.00 K(+4.1%) |
| Mar 2008 | - | -$96.00 K(-60.5%) | -$339.00 K(-81.9%) |
| Dec 2007 | - | -$243.00 K(<-9900.0%) | -$1.87 M(+15.0%) |
| Sept 2007 | $0.00(0.0%) | $0.00(0.0%) | -$1.63 M(0.0%) |
| June 2007 | - | $0.00(-100.0%) | -$1.63 M(+1.7%) |
| Mar 2007 | - | -$1.63 M(<-9900.0%) | -$1.60 M(-147.2%) |
| Dec 2006 | $0.00(-100.0%) | $0.00(0.0%) | $3.39 M(-78.9%) |
| Sept 2006 | - | $0.00(-100.0%) | $16.10 M(-17.2%) |
| June 2006 | - | $26.70 K(-99.2%) | $19.45 M(-14.2%) |
| Mar 2006 | - | $3.36 M(-73.5%) | $22.66 M(+2.0%) |
| Dec 2005 | $12.71 M(+35.7%) | $12.71 M(+279.0%) | $22.22 M(+83.9%) |
| Sept 2005 | - | $3.35 M(+3.6%) | $12.08 M(+9.4%) |
| June 2005 | - | $3.24 M(+10.5%) | $11.04 M(+9.0%) |
| Mar 2005 | - | $2.93 M(+14.1%) | $10.13 M(+8.2%) |
| Dec 2004 | $9.36 M(+45.4%) | $2.57 M(+11.0%) | $9.36 M(+37.8%) |
| Sept 2004 | - | $2.31 M(-0.4%) | $6.79 M(+51.6%) |
| June 2004 | - | $2.32 M(+7.4%) | $4.48 M(+107.4%) |
| Mar 2004 | - | $2.16 M | $2.16 M |
| Dec 2003 | $6.44 M | - | - |
FAQ
- What is NeuBase Therapeutics annual operaing income?
- What is the all time high annual operating profit for NeuBase Therapeutics?
- What is NeuBase Therapeutics quarterly operating income?
- What is the all time high quarterly operating profit for NeuBase Therapeutics?
- What is NeuBase Therapeutics TTM operating income?
- What is the all time high TTM operating profit for NeuBase Therapeutics?
What is NeuBase Therapeutics annual operaing income?
The current annual operating profit of NBSE is -$33.32 M
What is the all time high annual operating profit for NeuBase Therapeutics?
NeuBase Therapeutics all-time high annual operaing income is $12.71 M
What is NeuBase Therapeutics quarterly operating income?
The current quarterly operating profit of NBSE is -$1.59 M
What is the all time high quarterly operating profit for NeuBase Therapeutics?
NeuBase Therapeutics all-time high quarterly operating income is $12.71 M
What is NeuBase Therapeutics TTM operating income?
The current TTM operating profit of NBSE is -$13.38 M
What is the all time high TTM operating profit for NeuBase Therapeutics?
NeuBase Therapeutics all-time high TTM operating income is $22.66 M